News for Healthier Living

PreludeDx Announces First Independent Validation of AidaBreast(tm), the Only Multi-Omic Test to Predict Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer

Prelude Corporation (PreludeDx(r)), a leader in precision diagnostics for early-stage breast cancer, today announced results from the first independent validation of AidaBreast(tm), a novel multi-omic biosignature developed to predict a woman's 10-year risk of locoregional recurrence (LRR) and her individualized benefit from adjuvant radiation therapy (RT) following breast-conserving surgery.

December 10, 2025


December 12 2025

December 11 2025

December 10 2025

December 9 2025

December 8 2025

December 7 2025

December 6 2025

December 5 2025

December 4 2025

December 3 2025

December 2 2025

December 1 2025

November 30 2025

November 29 2025

November 28 2025